Dr. Alan Sandler will become President of Reeding Pharmaceuticals and Head of Global Development for Oncology, with nearly 30 years of experience in oncology and drug development.
during his tenure at Genente/Roche, he led the team in the development and approval of several innovative drugs worldwide, most recently the PD-L1 drug Tecentriq® (Tesanci®).
joined Gene Tektronick/Roche, Dr. Sandler was a professor at Oregon Health and Science University and head of the Hematology/Oncology Department.
, he taught at Indiana University and Vanderbilt University School of Medicine.
Sandler holds a Ph.D. from Rush Medical School and has completed medical training and research as a researcher in oncology at Yale University-NewArkland Medical Center.
has published more than 300 peer-reviewed publications, including articles, abstracts and chapters in books.
note: There are deletions in the original text